Pars Plana Vitrectomy Clinical Trial
Official title:
Safety and Preliminary Efficacy of Two Dose Levels of HydroLenz as a Protectant for Vitrectomy-Induced Lens Opacities in Subjects Undergoing Vitrectomy
The primary objective of this study is to provide safety data for two different dosages of HydroLenz. Secondary objectives are to provide preliminary data to determine whether HydroLenz has the same effect in humans as it does in the porcine model; to confirm the reliability of methods for evaluating lens opacity; and, to acquire information that can be used to design the pivotal study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05990829 -
Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial
|
Phase 4 | |
| Recruiting |
NCT05631054 -
Establishment and Validation of a Risk Prediction Model for Long-term Low Vision After Vitrectomy in PDR Patients
|
||
| Recruiting |
NCT05728476 -
Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema
|
N/A | |
| Recruiting |
NCT04774146 -
Quantification of Silicone Oil Emulsification After Pars Plana Vitrectomy
|
||
| Completed |
NCT04278079 -
Vitrectomy With Internal Limiting Membrane Peeling for Myopic Traction Maculopathy
|
N/A | |
| Completed |
NCT05013281 -
Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
|
||
| Completed |
NCT00548197 -
Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
|
Phase 1 | |
| Terminated |
NCT00936520 -
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
|
Phase 1 | |
| Recruiting |
NCT05248334 -
A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
|
Phase 1 |